Transcription of US-17452 --------------------------------- DOSAGE …
{{id}} {{{paragraph}}}
Example: bachelor of science
US-17452 --------------------------------- DOSAGE …
US-17452 HIGHLIGHTS OF PRESCRIBING INFORMATIONT hese highlights do not include all the information needed to use lynparza safely and effectively. See full prescribing information for (olaparib) tablets, for oral useInitial Approval: 2014------------------------------------ -- RECENT MAJOR CHANGES -------------------------------------Ind ications and Usage ( ) 1/2018 DOSAGE and Administration ( ) 1/2018 Warnings and Precautions (5) 1/2018---------------------------------- ---- INDICATIONS AND USAGE --------------------------------------Ly nparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:Ovarian cancer for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
LYNPARZA ® (olaparib) tablets, for oral use. 2. FULL PRESCRIBING INFORMATION . 1 INDICATIONS AND USAGE 1.1 Maintenance Treatment of Recurrent Ovarian Cancer
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Related search queries
NEW ZEALAND DATA SHEET, Epithelial Ovarian, NCCN Guideline Updates: Hereditary Breast and, NCCN Guideline Updates: Hereditary Breast and Ovarian, DNA MISMATCH REPAIR PROTEIN, DNA Mismatch Repair Protein hMSH6, Ovarian Cancer is Histotype-Specific, Telephone Directory, State, Directory, State Telephone Directory